Camber Pharmaceuticals continues to strengthen its range of treatment options with the introduction of Imatinib Mesylate Tablets [im-MA-ta-nib].
Imatinib is an oral targeted therapy used for several cancers and other conditions caused by specific genetic mutations.
Its approved indications include: Philadelphia chromosome positive chronic myeloid leukemia, gastrointestinal stromal tumors, Philadelphia chromosome positive acute lymphoblastic leukemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans.
For complete indications, click here.
Imatinib Mesylate Tablets are available in 30-count bottles of 400 mg and 90-count bottles of 100 mg.
